Jennifer Cackowski
Family Medicine · Binghamton, NYNPI 1467839258
Payments from drug & device makers
Across 131 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$732
- Gilead$650
- Teva Pharmaceuticals USA, Inc.$335
- Braeburn Inc.$282
- Indivior Inc.$260
- Alkermes, Inc.$121
- plus $495 from 10 others
What the payments were for
- Food & beverage$2,864100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $732 |
| Gilead | 30 | $650 |
| Teva Pharmaceuticals USA, Inc. | 16 | $335 |
| Braeburn Inc. | 4 | $282 |
| Indivior Inc. | 12 | $260 |
| Alkermes, Inc. | 6 | $121 |
| Viiv Healthcare Company | 1 | $102 |
| Johnson & Johnson | 3 | $91 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Sunovion Pharmaceuticals Inc. | 4 | $64 |
| Exact Sciences | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Organon | 2 | $19 |
| Orexo US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,875 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SublocadeBuprenorphine | 11 | $19,618 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 71 | $12,193 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $735 |
| Cyclobenzaprine Hcl | 11 | $226 |
| Levothyroxine Sodium | 16 | $204 |
| Pantoprazole Sodium | 19 | $184 |
| Atorvastatin Calcium | 31 | $175 |
| Gabapentin | 22 | $160 |
| Lisinopril | 33 | $142 |
| Omeprazole | 11 | $136 |
| Metformin Hcl | 29 | $97 |
| Amlodipine Besylate | 19 | $90 |
| Losartan Potassium | 11 | $60 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $46 |
| Hydrochlorothiazide | 13 | $10 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Sublocade | $260 | $19,61811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Binghamton
- Frank EderBinghamton$46.2M
- Sanjiv PatelBinghamton$41K
- Matthew DavisRochester$76.6M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.